CoChat

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

Abstract

EGF receptor (EGFR)-targeted monoclonal antibodies are effective in a subset of metastatic colorectal cancers. Inevitably, all patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases. We show that amplification of the MET proto-oncogene is associated with acquired resistance in tumors that do not develop KRAS mutations during anti-EGFR therapy. Amplification of the MET locus was present in circulating tumor DNA before relapse was clinically evident. Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors. These results highlight the role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer and encourage the use of MET inhibitors in patients displaying resistance as a result of MET amplification. Significance: Amplification of the MET proto-oncogene is responsible for de novo and acquired resistance to anti-EGFR therapy in a subset of colorectal cancers. As multiple anti-MET therapeutic strategies are available, these findings offer immediate novel opportunities to design clinical studies. Cancer Discov; 3(6); 658–73. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 591

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-12-0558

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Whitehead, 1985, A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer, J Natl Cancer Inst, 74, 759

Cited by

See all 687

Metadata

Authors
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., Apicella, M., Migliardi, G., Galimi, F., Lauricella, C., Zanon, C., Perera, T., Veronese, S., Corti, G., Amatu, A., Gambacorta, M., Diaz, L. A., Sausen, M., Velculescu, V. E., Comoglio, P., Trusolino, L., Di Nicolantonio, F., Giordano, S., & Siena, S.
Affiliations
  • Janssen (Belgium) (BE)
  • Authors' Affiliations: 1Department of Oncology, University of Torino; 2IRCC Institute for Cancer Research and Treatment at Candiolo, Candiolo, Torino; 3FIRC Institute of Molecular Oncology (IFOM); 4Division of Pathology and 5Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano, Italy;6Janssen Research and Development, Beerse, Belgium; and 7Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland
Corresponding author
  • Bardelli, Alberto
  • Giordano, Silvia
Venue
Cancer Discovery
Published
2013-06-01
Volume
3
Issue
6
Pages
658-673
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2007513598
Cited by
657
References
54
Citations by year
2026: 17 · 2025: 32 · 2024: 38 · 2023: 38 · 2022: 37 · 2021: 41 · 2020: 41 · 2019: 57 · 2018: 55 · 2017: 61 · 2016: 77 · 2015: 73 · 2014: 68 · 2013: 22
FWCI
42.81
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders
  • Swim Across America
  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • Associazione Italiana per la Ricerca sul Cancro
  • National Institutes of Health (5r01ca121113-15)
  • National Cancer Institute (R01-CA121113, CA-121113)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
anti-EGFR therapy resistance, KRAS mutation, circulating tumor DNA, MET inhibitors, colorectal cancer, patient-derived xenografts, acquired drug resistance
MeSH terms
Cetuximab, Panitumumab, Proto-Oncogene Mas, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Random Allocation, Genes, ras, Colorectal Neoplasms, Mice, SCID, Mice, Inbred NOD, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-12-0558
The paper
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., Apicella, M., Migliardi, G., Galimi, F., Lauricella, C., Zanon, C., Perera, T., Veronese, S., Corti, G., Amatu, A., . . . Siena, S. (2013). Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-12-0558

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.